The annual cost of treatment is approx'ly $300,000 per patient. $200MM divided by $300,000 is only 700 patients. In the US alone, there are many thousands of children (potential recipients of the drug) who are currently afflicted. Not to be too precise, but this indicates annual income in the BILLIONS of dollars.
Now do you understand why this company will soon be one of the Giant Biotech firms?. If you haven't yet bought in, time is running out for you. After tomorrow, you will never see the PPS in the $30's again.